Pelthos Therapeutics Inc.

Pelthos Therapeutics Inc. announced that CEO Scott Plesha will present at the Jefferies Global Healthcare Conference on June 4, 2026, and participate in one-on-one investor meetings. The company's lead product ZELSUVMI (berdazimer) showed 17% quarter-over-quarter revenue growth, reaching $10.7 million in Q1 2026.

Pelthos Therapeutics Inc. (PTHS) announced the acquisition of Xeglyze® (abametapir), an FDA-approved topical treatment for head lice, from Australian biotech company Hatchtech Pty Ltd. for $1.8 million. The acquisition adds a complementary product to Pelthos' portfolio with no future milestone or royalty payments owed. The company plans to relau...

Pelthos Therapeutics Inc. (NYSE American: PTHS) announced the appointment of veteran finance executive Andrew J. Einhorn to its Board of Directors effective immediately. Einhorn brings over four decades of experience in investment banking, capital markets, and C-level finance roles at life science companies. He will serve on the Audit Committee a...

Ligand Pharmaceuticals announced 2026 full year revenue guidance of $245-$285 million, representing a 15% core revenue growth, with strong expectations for royalty revenue from key pharmaceutical products.

Pelthos Therapeutics signed an agreement with a major Pharmacy Benefit Manager to expand patient access to ZELSUVMI, its FDA-approved topical gel for treating molluscum contagiosum, which affects an estimated 16.7 million people annually.